[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ebv-associated-tnk-cell-lymphoproliferative-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ebv-associated-tnk-cell-lymphoproliferative-diseases":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100630519",false,"NCT07488728","Letermovir Prophylaxis in Children With EBV-Positive T\u002FNK-Cell Lymphoproliferative Disease and Refractory\u002FRelapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","Impact of Letermovir Prophylaxis on Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation in Children With EBV-Positive T\u002FNK-Cell Lymphoproliferative Disease and Refractory\u002FRelapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n* Diagnosed with EBV-positive T\u002FNK lymphoproliferative disease (EBV-T\u002FNK LPD) according to ICC 2022 criteria, or diagnosed with refractory\u002Frelapsed EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) according to the 2004-HLH diagnostic criteria;\n* Undergoing first allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the study center;\n* Age \\\u003C 18 years;\n* CMV seropositive (IgG+) prior to transplantation;\n* Presence of at least one high-risk factor for CMV infection: haploidentical transplantation, HLA-mismatched transplantation, receipt of ATG (including ATLG\u002FALG) in conditioning, sustained corticosteroid use post-conditioning, donor\u002Frecipient CMV serostatus mismatch, or positive NGS result pre-transplant.\n\nExclusion Criteria:\n\n* History of CMV end-organ disease within 6 months prior to enrollment;\n* Severe hepatic dysfunction (defined as Child-Pugh Class C);\n* End-stage renal impairment with creatinine clearance \\\u003C 10 mL\u002Fmin (calculated by Cockcroft-Gault equation);\n* Prior allogeneic hematopoietic stem cell transplantation;\n* Expected survival ≤ 3 months;\n* Received radiation therapy during conditioning;\n* Initiation of letermovir prophylaxis after day 28 post-transplant;\n* Letermovir dosage or administration not in accordance with the prescribing information;\n* Lack of signed informed consent.","ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study investigates the impact of letermovir prophylaxis on viral infections (including CMV, EBV, BKV, HHV-6\u002F7, RSV, ADV, HSV, etc.) following allogeneic hematopoietic stem cell transplantation in pediatric patients with EBV-associated T\u002FNK-cell lymphoproliferative diseases and refractory\u002Frelapsed EBV-related hemophagocytic lymphohistiocytosis. Additionally, we examine its effects on other transplantation complications, including engraftment failure, graft-versus-host disease (GvHD), disease relapse, thrombotic microangiopathy (TMA), overall survival (OS), post-transplant lymphoproliferative disorder (PTLD) incidence, and immune reconstitution.",[25,26,27],"EBV-associated T\u002FNK-cell Lymphoproliferative Diseases","Refractory\u002FRelapsed EBV-related Hemophagocytic Lymphohistiocytosis","Letermovir",[29,27,30,31],"EBV","EBV-associated T\u002FNK-cell lymphoproliferative diseases","refractory\u002Frelapsed EBV-related hemophagocytic lymphohistiocytosis","RECRUITING","2026-03-18",{"date":35,"type":36},"2026-03-23","ACTUAL",{"date":38,"type":36},"2025-10-01",{"date":40,"type":19},"2026-12-31",{"name":42,"class":43},"Beijing Children's Hospital","OTHER",""]